Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus type 16 E7 induces significant tumor regression

Cancer Research

Volumn 70, Issue 10, 2010, Pages 3955-3964

  Kanodia, Shreya ^a,c   Da Silva, Diane M ^b,c   Karamanukyan, Tigran ^c   Bogaert, Lies ^d   Fu, Yang Xin ^e   Kast, W Martin ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d GHENT UNIVERSITY   (Belgium)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; CHEMOATTRACTANT; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 9; LYMPHOTOXIN BETA RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; PROTEIN E7; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; LYMPHOCYTIC INFILTRATION; LYMPHOID TISSUE; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR REGRESSION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS PARTICLE;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; FEMALE; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PEPTIDE FRAGMENTS; REPLICON; SURVIVAL RATE; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; VACCINATION;

EID: 77952833756     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3773     Document Type: Article

References (36)

1. Nasiell K. Roger V. Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up Obstetrics and Gynecology 1986 67 5 665-669 1. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67:665-669 (Pubitemid 16111924)
2. Benton C, Shyahidullah H, Hunter JAM. Human papillomavirus in the immunocompromised. Papillomavirus Rep 1999;3:23-26
3. Laga M, Icenogle JP, Marsella R, et al. Genital papillomavirus infection and cervical dysplasia - opportunistic complications of HIV infection. Int J Cancer 1992;50:45-48
4. Maiman M. Fruchter R.G. Serur E. Remy J.C. Feuer G. Boyce J. Human immunodeficiency virus infection and cervical neoplasia Gynecologic Oncology 1990 38 3 377-382 DOI 10.1016/0090-8258(90)90077-X 4. Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 1990;38:377-382 (Pubitemid 20362560)
5. Rudlinger R. Smith I.W. Bunney M.H. Hunter J.A.A. Human papillomavirus infections in a group of renal transplant recipients British Journal of Dermatology 1986 115 6 681-692 DOI 10.1111/j.1365-2133.1986.tb06649.x 5. Rudlinger R, Smith IW, Bunney MH, Hunter JA. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986;115:681-692 (Pubitemid 17181893)
6. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-774
7. Rogozinski TT, Jablonska S, Jarzabek-Chorzelska M. Role of cell-mediated immunity in spontaneous regression of plane warts. Int J Dermatol 1988;27:322-326
8. Kanodia S. Da Silva D.M. Kast W.M. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions International Journal of Cancer 2008 122 2 247-259 DOI 10.1002/ijc.23252 8. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008;122:247-259 (Pubitemid 350234709)
9. Schlesinger S. Dubensky T.W. Jr. Alphavirus vectors for gene expression and vaccines Current Opinion in Biotechnology 1999 10 5 434-439 DOI 10.1016/S0958-1669(99)00006-3 9. Schlesinger S, Dubensky TW. Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol 1999;10:434-439 (Pubitemid 29457267)
10. Pushko P. Parker M. Ludwig G.V. Davis N.L. Johnston R.E. Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo Virology 1997 239 2 389-401 DOI 10.1006/viro.1997.8878 10. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997;239:389-401. (Pubitemid 28105644)
11. Hevey M. Negley D. Pushko P. Smith J. Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates Virology 1998 251 1 28-37 DOI 10.1006/viro.1998.9367 11. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998;251:28-37. (Pubitemid 28527716)
12. Caley I.J. Betts M.R. Davis N.L. Swanstrom R. Frelinger J.A. Johnston R.E. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy Vaccine 1999 17 23 24 3124-3135 DOI 10.1016/S0264-410X(99)00142-5, PII S0264410X99001425 12. Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 1999;17:3124-3135 (Pubitemid 29366994)
13. Davis NL, Caley IJ, Brown KW, et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 2000;74:371-378
14. Pushko P. Bray M. Ludwig G.V. Parker M. Schmaljohn A. Sanchez A. Jahrling P.B. Smith J.F. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus Vaccine 2000 19 1 142-153 DOI 10.1016/S0264-410X(00)00113-4, PII S0264410X00001134 14. Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000;19:142-153 (Pubitemid 30618964)
15. Velders M.P. McElhiney S. Cassetti M.C. Eiben G.L. Higgins T. Kovacs G.R. Elmishad A.G. Kast W.M. Smith L.R. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA Cancer Research 2001 61 21 7861-7867 15. Velders MP, McElhiney S, Cassetti MC, et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 2001;61:7861-7867 (Pubitemid 33049376)
16. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005;23:787-819.
17. Fu Y.X. Chaplin D.D. Development and maturation of secondary lymphoid tissues Annual Review of Immunology 1999 17 399-433 DOI 10.1146/annurev.immunol. 17.1.399 17. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999;17:399-433. (Pubitemid 29241130)
18. Cyster J.G. Chemokines and cell migration in secondary lymphoid organs Science 1999 286 5447 2098-2102 18. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286:2098-2102 (Pubitemid 129516279)
19. Ruddle NH. Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol Res 1999;19:119-125
20. Mauri DN, Ebner R, Montgomery RI, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 1998;8:21-30.
21. Rooney IA, Butrovich KD, Glass AA, et al. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 2000;275:14307-14315
22. Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 2003;3:642-655
23. Tamada K. Shimozaki K. Chapoval A.I. Zhu G. Sica G. Flies D. Boone T. Hsu H. Fu Y.-X. Nagata S. Ni J. Chen L. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway Nature Medicine 2000 6 3 283-289 DOI 10.1038/73136 23. Tamada K, Shimozaki K, Chapoval AI, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000;6:283-289 (Pubitemid 30148620)
24. Wang J. Lo J.C. Foster A. Yu P. Chen H.M. Wang Y. Tamada K. Chen L. Fu Y.-X. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT Journal of Clinical Investigation 2001 108 12 1771-1780 DOI 10.1172/JCI200113827 24. Wang J, Lo J, Foster A, et al. The regulation of T cell homeostasis and autoimmunity by T cell derived LIGHT. J Clinic Invest 2001:1771-1780 (Pubitemid 34015122)
25. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-2249
26. Feltkamp MC, Vreugdenhil GR, Vierboom MP, et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995;25:2638-2642
27. van Hall T, van de Rhee NE, Schoenberger SP, et al. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res 1998;58:3087-3093
28. Garcia-Hernandez M.D.L.L. Gray A. Hubby B. Klinger O.J. Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity Cancer Research 2008 68 3 861-869 http://cancerres.aacrjournals.org/cgi/reprint/68/3/861 DOI 10.1158/0008-5472.CAN-07-0445 28. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008;68:861-869 (Pubitemid 351206764)
29. Cassetti M.C. McElhiney S.P. Shahabi V. Pullen J.K. Le Poole I.C. Eiben G.L. Smith L.R. Kast W.M. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes Vaccine 2004 22 3 4 520-527 DOI 10.1016/j.vaccine.2003.07.003 29. Cassetti MC, McElhiney SP, Shahabi V, et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004;22:520-527 (Pubitemid 37510284)
30. Yu P, Lee Y, Wang Y, et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 2007;179:1960-1968
31. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007;67:1344-1351
32. Wang J. Foster A. Chin R. Yu P. Sun Y. Wang Y. Pfeffer K. Fu Y.-X. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function European Journal of Immunology 2002 32 7 1969-1979 DOI 10.1002/1521-4141(200207) 32:7<1969::AID-IMMU1969>3.0.CO;2-M 32. Wang J, Foster A, Chin R, et al. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur J Immunol 2002;32:1969-1979 (Pubitemid 34814553)
33. Sharma S. Stolina M. Luo J. Strieter R.M. Burdick M. Zhu L.X. Batra R.K. Dubinett S.M. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo Journal of Immunology 2000 164 9 4558-4563 33. Sharma S, Stolina M, Luo J, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000;164:4558-4563 (Pubitemid 30238052)
34. Sharma S, Yang SC, Hillinger S, et al. SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2003;2:22.
35. Petreaca ML, Yao M, Ware C, Martins-Green MM. Vascular endothelial growth factor promotes macrophage apoptosis through stimulation of tumor necrosis factor superfamily member 14 (TNFSF14/LIGHT). Wound Repair Regen 2008;16:602-614
36. Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumor escape. Semin Cancer Biol 2002;12:25-31.